Gilead Sciences has picked up a new inflammatory disease program from China’s PepStar Therapeutics to pair with the Phase 2 ...
RNAi specialist Alnylam Pharmaceuticals will advance the Huntington’s disease drug brezosiran into a placebo-controlled study ...
Turkey’s medical-tourism market reached an estimated $3.5 billion in 2025, with hair transplantation accounting for 51.9% of ...
Labcorp intends to be the first commercial laboratory to offer FDA-approved HPV testing with the BD Onclarity™ HPV Assay ...
U.S. Patent No. 12,734,179 B2, titled Progesterone formulation to trigger ovulation and provide luteal phase support, was ...
A combination of Tango Therapeutics’ vopimetostat and Revolution Medicines’ recently approved Rasonque led to a response rate ...
Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology ...
First reported clinical evaluation of an allogeneic CD19-directed CAR T-cell therapy in progressive MS demonstrated an ...
Completion of light dose-escalation Part A of Phase 1 study identifies regimen for further evaluation in Part B, supporting ...
(Biokin) reported positive results from a prespecified interim analysis of the randomized Phase 3 PANKU-Breast01 study ...
Financing will support Star’s next phase of growth, including advancement of current preclinical programs into the clinic and ...
MESA, AZ / ACCESS Newswire / October 23, 2026 / Medical Care Technologies Inc. (OTCID:MDCE) today announced that it is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results